(CercleFinance.com) – PCAS publishes for 2022 a net result of -48.8 million euros, against -40.5 million in 2021, despite an EBITDA that rose from -4.6 to +2.2 million from a year on year, for a turnover up by 21.1% to 226.4 million (+17.9% at constant exchange rates).
The chemist explains that his results were affected by ‘a level of activity still insufficient to cover the fixed costs on several sites in pharmaceutical synthesis, as well as by inventory write-downs relating to non-compliant products’.
PCAS indicates that the return to positive results, announced for 2023, is deferred, but that it “continues to benefit from the support of its majority shareholder Seqens for the financing of its activities and its development”.